| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
The purpose of this study was to establish a method for estimating the efficacy of the molecular-targeting agent cetuximab (C-mab) for oral squamous cell carcinoma (OSCC). First, the sensitivity of OSCC cell lines and clinical specimens to C-mab was investigated. The sensitivity varied among cell lines, while 30% of the clinical specimens showed sensitivity. It has been reported that variations of the EGFR cause differences in sensitivity. Accordingly, surgical specimens were investigated for the expression of variant EGFR. As a result, the positivity rate was 100% and 12.5% for the wild-type and variant EGFR, respectively. These results suggest that there are other factors related to resistance in addition to EGFR variations.
|
